Focused On-demand Library for E3 ubiquitin-protein ligase RNF217

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8TC41

UPID:

RN217_HUMAN

Alternative names:

IBR domain-containing protein 1; Opposite STL; RING finger protein 217

Alternative UPACC:

Q8TC41; H7C5V4; Q5TCA4; Q9BX48

Background:

E3 ubiquitin-protein ligase RNF217 plays a pivotal role in cellular processes by transferring ubiquitin to substrates, influencing their degradation. It specifically targets the iron exporter ferroportin/SLC40A1, crucial for iron homeostasis. Known alternatively as IBR domain-containing protein 1, Opposite STL, and RING finger protein 217, its unique function underscores its biological significance.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase RNF217 could open doors to potential therapeutic strategies, especially in disorders related to iron metabolism and homeostasis.